rf-fullcolor.png

 

August 23, 2016
by Michael Mezher

FDA Clears Test for Measuring Post-Concussion Cognitive Function

The US Food and Drug Administration (FDA) on Monday announced it cleared the first computer-based tests for measuring cognitive function after a suspected concussion in both adults and children.

Concussions have been a growing concern in recent years, as a growing body of evidence suggests the potential for concussions to have long-term health implications, especially in sports such as football and ice hockey where players are at a high risk for head injuries in both practice and competition.

According to the US Centers for Disease Control and Prevention (CDC), traumatic brain injuries were linked to approximately 2.5 million emergency room visits, hospitalizations or deaths in 2010, and are occurring at an increasing rate in children under 19.

"The Immediate Post-Concussion Assessment and Cognitive Testing (ImPACT) and ImPACT Pediatric are the first medical devices permitted for marketing that are intended to assess cognitive function following a possible concussion [and] are intended as part of the medical evaluation that doctors perform to assess signs and symptoms of head injury," FDA says.

However, the agency says the tests are not meant to diagnose concussions themselves, or determine how to treat patients.

"Instead the devices are meant to test cognitive skills such as word memory, reaction time and word recognition, all of which could be affected by a head injury. The results are compared to an age-matched control database or to a patient's pre-injury baseline scores, if available."

The tests were developed by Pittsburgh-based company ImPACT Applications and were reviewed by FDA through its de novo classification process, as no similar tests had been previously cleared by the agency.

According to FDA, ImPACT Applications submitted more than 250 peer-reviewed articles analyzing the ImPACT tests "including the devices' validity, reliability and ability to detect evidence of cognitive dysfunction that might be associated with a concussive head injury."

FDA

×

Welcome to the new RAPS Digital Experience

We have completed our migration to a new platform and are pleased to introduce the updated site.

What to expect: If you have an existing login, please RESET YOUR PASSWORD before signing in. After you log in for the first time, you will be prompted to confirm your profile preferences, which will be used to personalize content.

We encourage you to explore the new website and visit your updated My RAPS page. If you need assistance, please review our FAQ page.

We welcome your feedback. Please let us know how we can continue to improve your experience.